Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Oct;28(4):552–560. doi: 10.1128/aac.28.4.552

Antiviral activity of 5-ethyl-2'-deoxyuridine against herpes simplex viruses in cell culture, mice, and guinea pigs.

R F Schinazi, R T Scott, J Peters, V Rice, A J Nahmias
PMCID: PMC180304  PMID: 3000291

Abstract

The susceptibility of 3 laboratory strains and 24 clinical isolates of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) to 5-ethyl-2'-deoxyuridine was determined in plaque reduction assays in Vero cells. The median effective doses were 8.6 and 7.8 microM, respectively. The drug was less potent than acyclovir and other related antiviral drugs, but it had a high therapeutic index against both HSV-1 and HSV-2. Drug-resistant viruses were readily produced in cell culture. These variants were cross-resistant to acyclovir, 2'-fluoro-5-iodoaracytosine, and 2'-fluoro-5-methylarauracil but were susceptible to vidarabine or phosphonoformate. These findings confirm that the selective antiviral activity of 5-ethyl-2'-deoxyuridine is mediated by the virus-induced thymidine kinase. Oral or intraperitoneal administration of the drug at nontoxic doses was ineffective in protecting mice against intracerebral challenge with virus. Using implanted osmotic minipumps or coadministering the drug with dimethyl sulfoxide failed to decrease the mortality rate. In guinea pigs infected genitally with HSV-2, topical drug treatment was more effective than placebo in reducing lesion severity and other clinical and virological variables. These effects were noted whether the drug treatment was initiated 3 or 24 h after infection (ascertained serologically). Drug-treated animals had a significantly lower herpes antibody titer than did placebo-treated guinea pigs, suggesting that the drug can also reduce the viral antigen load. In this model, the drug appeared to be as effective as topical phosphonoformate or acyclovir.

Full text

PDF
557

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker D. C., Kumar S. D., Waites W. J., Arnett G., Shannon W. M., Higuchi W. I., Lambert W. J. Synthesis and evaluation of a series of 2'-O-acyl derivatives of 9-beta-D-arabinofuranosyladenine as antiherpes agents. J Med Chem. 1984 Mar;27(3):270–274. doi: 10.1021/jm00369a007. [DOI] [PubMed] [Google Scholar]
  2. Bernstein D. I., Lovett M. A., Bryson Y. J. The effects of acyclovir on antibody response to herpes simplex virus in primary genital herpetic infections. J Infect Dis. 1984 Jul;150(1):7–13. doi: 10.1093/infdis/150.1.7. [DOI] [PubMed] [Google Scholar]
  3. Broadwell R. D., Salcman M., Kaplan R. S. Morphologic effect of dimethyl sulfoxide on the blood-brain barrier. Science. 1982 Jul 9;217(4555):164–166. doi: 10.1126/science.7089551. [DOI] [PubMed] [Google Scholar]
  4. Cheng Y. C., Domin B. A., Sharma R. A., Bobek M. Antiviral action and cellular toxicity of four thymidine analogues: 5-ethyl-,5-vinyl-, 5-propyl-, and 5-allyl-2'- deoxyuridine. Antimicrob Agents Chemother. 1976 Jul;10(1):119–122. doi: 10.1128/aac.10.1.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cheng Y. C., Schinazi R. F., Dutschman G. E., Tan R. S., Grill S. P. Virus-induced thymidine kinases as markers for typing herpes simplex viruses and for drug sensitivity assays. J Virol Methods. 1982 Nov;5(3-4):209–217. doi: 10.1016/0166-0934(82)90011-8. [DOI] [PubMed] [Google Scholar]
  6. Coleman R. M., Bailey P. D., Whitley R. J., Keyserling H., Nahmias A. J. ELISA for the detection of herpes simplex virus antigens in the cerebrospinal fluid of patients with encephalitis. J Virol Methods. 1983 Sep;7(3):117–125. doi: 10.1016/0166-0934(83)90001-0. [DOI] [PubMed] [Google Scholar]
  7. Davis W. B., Oakes J. E., Taylor J. A. Effect of treatment with 5-ethyl-2'-deoxyuridine on herpes simplex virus encephalitis in normal and immunosuppressed mice. Antimicrob Agents Chemother. 1978 Nov;14(5):743–748. doi: 10.1128/aac.14.5.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Davis W. B., Oakes J. E., Vacik J. P., Rebert R. R., Taylor J. A. 5-Ethyl-2'-deoxyuridine as a systemic agent for treatment of herpes simplex virus encephalitis. Comparison of effects in a normal and immunosuppressed murine model. Adv Ophthalmol. 1979;38:140–150. [PubMed] [Google Scholar]
  9. De Clercq E., Shugar D. Antiviral activity of 5-ethyl pyrimidine deoxynucleosides. Biochem Pharmacol. 1975 May 15;24(10):1073–1078. doi: 10.1016/0006-2952(75)90192-6. [DOI] [PubMed] [Google Scholar]
  10. Diana G. D., Zalay E. S., Salvador U. J., Pancic F., Steinberg B. Synthesis of some phosphonates with antiherpetic activity. J Med Chem. 1984 May;27(5):691–694. doi: 10.1021/jm00371a024. [DOI] [PubMed] [Google Scholar]
  11. Donnenberg A. D., Chaikof E., Aurelian L. Immunity to herpes simplex virus type 2: cell-mediated immunity in latently infected guinea pigs. Infect Immun. 1980 Oct;30(1):99–109. doi: 10.1128/iai.30.1.99-109.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ellis M. N., Barry D. W. Oral acyclovir therapy of genital herpes simplex virus type 2 infections in guinea pigs. Antimicrob Agents Chemother. 1985 Feb;27(2):167–171. doi: 10.1128/aac.27.2.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Elze K. L. Ten years of clinical experiences with ethyldeoxyuridine. Adv Ophthalmol. 1979;38:134–139. [PubMed] [Google Scholar]
  14. Fraser-Smith E. B., Smee D. F., Matthews T. R. Efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine against primary and recrudescent genital herpes simplex virus type 2 infections in guinea pigs. Antimicrob Agents Chemother. 1983 Dec;24(6):883–887. doi: 10.1128/aac.24.6.883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gauri K. K., Malorny G. Chemotherapie der Herpes-Infektion mit neuen 5-Alkyluracildesoxyribosiden. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1967;257(1):21–22. [PubMed] [Google Scholar]
  16. Gauri K. K., Malorny G., Riehm E. Einfluss von 5-Athyl-2'-desoxyuridin (ADU) auf die Regeneration der experimentell geschädigten Cornea. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1970;179(4):287–293. doi: 10.1007/BF00427853. [DOI] [PubMed] [Google Scholar]
  17. Gauri K. K., Malorny G., Schiff W. Immunobiological studies with the virostatics 5-ethyl-2'-deoxyuridine (EDU) and 1-allyl-3,5-diethyl-6-chlorouracil (ACIU). Chemotherapy. 1969;14(3):129–132. doi: 10.1159/000220621. [DOI] [PubMed] [Google Scholar]
  18. Gauri K. K., Pflughaupt K. W., Müller R. Synthese und photochemische Eigenschaften von 1'-(2'-Desoxy-beta-D-ribofuranosyl)-(4-3H)-5-äthyluracil. Z Naturforsch B. 1969 Jul;24(7):833–836. [PubMed] [Google Scholar]
  19. Gauri K. K., Shif I., Wolford R. G. Failure of 5-ethyl-2'-deoxyuridine to induce oncogenic RNA (oncorna) viruses in Fischer rat embryo cells and in Balb/3T3 mouse cells. Biochem Pharmacol. 1976 Aug 1;25(15):1809–1810. doi: 10.1016/0006-2952(76)90420-2. [DOI] [PubMed] [Google Scholar]
  20. Gauri K. K. Subkonjunktivale Applikation vom 5-Athyl-2'-desoxyuridin (ADU) zur Chemotherapie der experimentellen Herpes-Keratitis beim Kaninchen. Klin Monbl Augenheilkd. 1968;153(6):837–840. [PubMed] [Google Scholar]
  21. Hsiung G. D., Mayo D. R., Lucia H. L., Landry M. L. Genital herpes: pathogenesis and chemotherapy in the guinea pig model. Rev Infect Dis. 1984 Jan-Feb;6(1):33–50. doi: 10.1093/clinids/6.1.33. [DOI] [PubMed] [Google Scholar]
  22. Kaul R., Kiefer G., Erhardt S., Hempel B. 2-14C-1-(2'-deoxy-beta-D-ribofuranosyl)-5-ethyluracil: synthesis and biotransformation in rats. J Pharm Sci. 1980 May;69(5):531–534. doi: 10.1002/jps.2600690514. [DOI] [PubMed] [Google Scholar]
  23. Kern E. R. Acyclovir treatment of experimental genital herpes simplex virus infections. Am J Med. 1982 Jul 20;73(1A):100–108. doi: 10.1016/0002-9343(82)90073-0. [DOI] [PubMed] [Google Scholar]
  24. Kern E. R., Glasgow L. A., Overall J. C., Jr, Reno J. M., Boezi J. A. Treatment of experimental herpesvirus infections with phosphonoformate and some comparisons with phosphonoacetate. Antimicrob Agents Chemother. 1978 Dec;14(6):817–823. doi: 10.1128/aac.14.6.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kowalzick L., Gauri K. K., Spadari S., Pedrali-Noy G., Koch G. Differential substrate specificity of DNA polymerase beta and of a DNA polymerase induced by herpes simplex virus type 2 towards thymidine triphosphate analogues. J Gen Virol. 1984 Mar;65(Pt 3):467–475. doi: 10.1099/0022-1317-65-3-467. [DOI] [PubMed] [Google Scholar]
  26. Kubilus J., Lee L. D., Baden H. P. Purification of thymidine phosphorylase from human amniochorion. Biochim Biophys Acta. 1978 Nov 10;527(1):221–228. doi: 10.1016/0005-2744(78)90271-1. [DOI] [PubMed] [Google Scholar]
  27. Kulikowski T., Shugar D. 13-Alkylpyrimidine nucleosides. Preparation and properties of 5-ethyl-2'-deoxycytidine and related nucleosides. J Med Chem. 1974 Mar;17(3):269–273. doi: 10.1021/jm00249a003. [DOI] [PubMed] [Google Scholar]
  28. Künkel H. A., Gauri K. K., Malorny G. Keine Mutationsauslösung durch 5-Athyl-2'-desoxyuridin (ADU) bei Drosophila melanogaster. Biophysik. 1968 Aug 12;5(1):88–90. doi: 10.1007/BF01388137. [DOI] [PubMed] [Google Scholar]
  29. Lafferty W. E., Brewer L. A., Corey L. Alteration of lymphocyte transformation response to herpes simplex virus infection by acyclovir therapy. Antimicrob Agents Chemother. 1984 Dec;26(6):887–891. doi: 10.1128/aac.26.6.887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Landry M. L., Lucia H. L., Hsiung G. D., Pronovost A. D., Dann P. R., August M. J., Mayo D. R. Effect of acyclovir on genital infection with herpes simplex virus types 1 and 2 in the guinea pig. Am J Med. 1982 Jul 20;73(1A):143–150. doi: 10.1016/0002-9343(82)90080-8. [DOI] [PubMed] [Google Scholar]
  31. Lukás B., Wiesendanger W., Schmidt-Ruppin K. H. Herpes genitalis in guinea-pigs. I. Kinetic study in infection with Herpesvirus hominis type 2. Arch Virol. 1975;41(1):1–11. doi: 10.1007/BF02175590. [DOI] [PubMed] [Google Scholar]
  32. Mayo D. R., Lucia H. L., Hsiung G. D. Effect of phosphonoformate on symptomatic genital herpes simplex virus type 2 infection of guinea pigs. Intervirology. 1983;19(1):26–32. doi: 10.1159/000149333. [DOI] [PubMed] [Google Scholar]
  33. Myerson D., Hsiung G. D. Prophylactic and therapeutic treatment with acyclovir of genital herpes in the guinea pig. Proc Soc Exp Biol Med. 1983 Nov;174(2):147–152. doi: 10.3181/00379727-174-41717. [DOI] [PubMed] [Google Scholar]
  34. Pronovost A. D., Lucia H. L., Dann P. R., Hsiung G. D. Effect of acyclovir on genital herpes in guinea pigs. J Infect Dis. 1982 Jun;145(6):904–908. doi: 10.1093/infdis/145.6.904. [DOI] [PubMed] [Google Scholar]
  35. Schinazi R. F., Peters J., Sokol M. K., Nahmias A. J. Therapeutic activities of 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5-iodocytosine and -thymine alone and in combination with acyclovir and vidarabine in mice infected intracerebrally with herpes simplex virus. Antimicrob Agents Chemother. 1983 Jul;24(1):95–103. doi: 10.1128/aac.24.1.95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Schinazi R. F., Peters J., Williams C. C., Chance D., Nahmias A. J. Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice. Antimicrob Agents Chemother. 1982 Sep;22(3):499–507. doi: 10.1128/aac.22.3.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Scriba M. Recurrent genital Herpes simplex virus (HSV) infection of guinea pigs. Med Microbiol Immunol. 1976 Dec 1;162(3-4):201–208. doi: 10.1007/BF02120998. [DOI] [PubMed] [Google Scholar]
  38. Scriba M., Tatzber F. Pathogenesis of Herpes simplex virus infections in guinea pigs. Infect Immun. 1981 Dec;34(3):655–661. doi: 10.1128/iai.34.3.655-661.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Shannon W. M., Arnett G., Drennen D. J. Lack of efficacy of 2-deoxy-D-glucose in the treatment of experimental herpes genitalis in guinea pigs. Antimicrob Agents Chemother. 1982 Mar;21(3):513–515. doi: 10.1128/aac.21.3.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Singh S., Willers I., Goedde H. W. 5-Ethyl-2'-deoxyuridine: absence of effects on the chromosomes of human lymphocytes and fibroblasts in culture. Humangenetik. 1974;24(2):135–139. doi: 10.1007/BF00283770. [DOI] [PubMed] [Google Scholar]
  41. Spruance S. L., Freeman D. J., Sheth N. V. Comparison of topically applied 5-ethyl-2'-deoxyuridine and acyclovir in the treatment of cutaneous herpes simplex virus infection in guinea pigs. Antimicrob Agents Chemother. 1985 Jul;28(1):103–106. doi: 10.1128/aac.28.1.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Stanberry L. R., Kern E. R., Richards J. T., Abbott T. M., Overall J. C., Jr Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J Infect Dis. 1982 Sep;146(3):397–404. doi: 10.1093/infdis/146.3.397. [DOI] [PubMed] [Google Scholar]
  43. Swierkowski M., Shugar D. A nonmutagenic thymidine analog with antiviral activity. 5-Ethyldeoxyuridine. J Med Chem. 1969 May;12(3):533–534. doi: 10.1021/jm00303a617. [DOI] [PubMed] [Google Scholar]
  44. Teh C. Z., Sacks S. L. Susceptibility of recent clinical isolates of herpes simplex virus to 5-ethyl-2'-deoxyuridine: preferential inhibition of herpes simplex virus type 2. Antimicrob Agents Chemother. 1983 May;23(5):637–640. doi: 10.1128/aac.23.5.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Vince R., Daluge S., Lee H., Shannon W. M., Arnett G., Schafer T. W., Nagabhushan T. L., Reichert P., Tsai H. Carbocyclic arabinofuranosyladenine (cyclaradine): efficacy against genital herpes in guinea pigs. Science. 1983 Sep 30;221(4618):1405–1406. doi: 10.1126/science.6684328. [DOI] [PubMed] [Google Scholar]
  46. Wade J. C., Day L. M., Crowley J. J., Meyers J. D. Recurrent infection with herpes simplex virus after marrow transplantation: role of the specific immune response and acyclovir treatment. J Infect Dis. 1984 May;149(5):750–756. doi: 10.1093/infdis/149.5.750. [DOI] [PubMed] [Google Scholar]
  47. Woodman P. W., Sarrif A. M., Heidelberger C. Specificity of pyrimidine nucleoside phosphorylases and the phosphorolysis of 5-fluoro-2'-deoxyuridine. Cancer Res. 1980 Mar;40(3):507–511. [PubMed] [Google Scholar]
  48. ZIMMERMAN M., SEIDENBERG J. DEOXYRIBOSYL TRANSFER. I. THYMIDINE PHOSPHORYLASE AND NUCLEOSIDE DEOXYRIBOSYLTRANSFERASE IN NORMAL AND MALIGNANT TISSUES. J Biol Chem. 1964 Aug;239:2618–2621. [PubMed] [Google Scholar]
  49. Zheng Z. M., Hsiung G. D. Complement-requiring neutralizing antibody in guinea pigs with primary and recurrent genital herpes. Proc Soc Exp Biol Med. 1984 Nov;177(2):332–336. doi: 10.3181/00379727-177-41952. [DOI] [PubMed] [Google Scholar]
  50. Zheng Z. M., Mayo D. R., Hsiung G. D. Effect of CP-20,961 on genital herpes in guinea pigs. Antiviral Res. 1983 Nov;3(4):275–283. doi: 10.1016/0166-3542(83)90006-2. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES